Biological investigations in deep venous thrombosis? Which conditions and what cost?;Bilan biologique de la thrombose veineuse: Quelles conditions et quel coût?

Sang Thrombose Vaisseaux

Volumn 18, Issue 10, 2006, Pages 523-528

  Sié, Pierre ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C; PROTEIN S;

DEEP VEIN THROMBOSIS; EDITORIAL; HEMOSTASIS; HUMAN; THROMBOPHILIA;

EID: 33846227985     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: 10.1684/stv.2006.0039     Document Type: Editorial

References (28)

1. de Moerloose P, Bounameaux HR, Mannucci PM. Screening test for thrombophilic patients: which tests, for which patient, by whom, when, and why? Semin Thromb Hemost 1998; 24: 321-7.
2. Wautrecht J-C. Venous thromboembolic disease: which coagulation screening, for whom, when? Rev Med Brux 2005; 26: S315-S319.
3. Tripodi A. Issues concerning the laboratory investigation of inherited thrombophilia. Mol Diagn 2005; 9: 181-6.
4. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005; 25: 1992-7.
5. British committee for standards in Haematology. Guideline. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-28.
6. Lyons S, Galloway MJ, Osgerby J, Hanley J. An audit of thrombophilia screens: results from the National Pathology Alliance benchmarking review. J Clin Pathol 2006; 59: 156-9.
7. Keijzer MB, Verhoef P, Borm GF, Blom HJ, den Heijer M. No added value of the methionine loading task in assessment for venous thrombosis and cardiovascular disease risk. Thromb Haemost 2006; 95: 380-5.
8. Tirado I, Mateo J, Soria JM, et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93: 468-74.
9. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003; 1: 410-1.
10. Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003; 1: 412-3.
11. Jennings I, Kitchen S, Woods TA, Preston FE. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation). Quality Assurance Program Semin Thromb Hemost 2005; 31: 66-72.
12. Meijer P, Kluft C, Haverkate F, De Maat MP. The long-term within- and between-laboratory variability for assay of antithrombin, and proteins C and S: results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation. J Thromb Haemost 2003; 1: 748-53.
13. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-41.
14. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L. Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S, and antithrombin deficiency and the potential high risk of a false positive diagnosis. Lab Hematol 2005; 11: 174-84.
15. Hellmann EA, Leslie ND, Moll S. Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost 2003; 1: 2335-9.
16. Morelli VM, De Visser MC, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 2005; 3: 183-5.
17. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-16.
18. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3: 459-64.
19. Cosmi B, Coccheri S. Thrombophilia in young women candidate to the pill: reasons for and against screening. Pathophysiol Haemost Thromb 2002; 32: 315-7.
20. van Korlaar IM, Vossen CY, Rosendaal FR, et al. Attitudes toward genetic testing for thrombophilia in asymptomatic members of a large family with heritable protein C deficiency. J Thromb Haemost 2005; 3: 2437-44.
21. Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98: 21-2.
22. Spencer FA, Goldberg R. Asymptomatic thrombophilia-a family affair. J Thromb Haemost 2005; 3: 457-8.
23. Pernod G, Jouk PS, Bosson JL, Carpentier PH, Polack B. More on: asymptomatic thrombophilia-a family affair. J Thromb Haemost 2005; 6: 1329-30.
24. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 72: 646-51.
25. Wu O, Robertson L, Twaddle S, et al The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131: 80-90.
26. Keeling D. Universal or selected screening for thrombophilia. Br J Haematol 2006; 133: 106-7.
27. Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 2004; 116: 816-28.
28. Brotman DJ. Why not test for hypercoagulability in patients with idiopathic venous thromboembolism? Am J Med 2004; 117: 801.